Cellular immunotherapies
Total Trials
16
As Lead Sponsor
15
As Collaborator
1
Total Enrollment
1,154
NCT02401815
CGT9486 (Formerly Known as PLX9486) as a Single Agent and in Combination With PLX3397 (Pexidartinib) or Sunitinib in Participants With Advanced Solid Tumors
Phase: Phase 1/2
Role: Lead Sponsor
Start: Mar 6, 2015
Completion: May 11, 2020
NCT02776813
Study of ACTR087 in Subjects With Relapsed or Refractory B-cell Lymphoma
Phase: Phase 1
Start: Aug 31, 2016
Completion: Feb 12, 2020
NCT02840110
Long-Term Follow-Up Study of Subjects Treated With ACTR T Cell Product
Phase: N/A
Start: Oct 31, 2016
Completion: Feb 23, 2021
NCT03189836
Study of ACTR707 in Combination With Rituximab in Subjects With Relapsed or Refractory B Cell Lymphoma
Start: Oct 4, 2017
Completion: Sep 21, 2020
NCT03266692
Study of ACTR087 in Combination With SEA-BCMA in Subjects With Relapsed or Refractory Multiple Myeloma
Start: Feb 22, 2018
Completion: Oct 1, 2019
NCT03680560
Study of ACTR T Cell Product in Combination With Trastuzumab in Subjects With HER2-Positive Advanced Solid Tumor Cancers
Start: Mar 13, 2019
Completion: Mar 12, 2020
NCT04996875
(Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis
Phase: Phase 2
Start: Nov 9, 2021
Completion: Jul 31, 2026
NCT05208047
(Peak) A Phase 3 Randomized Trial of CGT9486+Sunitinib vs. Sunitinib in Subjects With Gastrointestinal Stromal Tumors
Phase: Phase 3
Start: Apr 14, 2022
Completion: Sep 30, 2026
NCT05186753
(Summit) a Study to Evaluate the Efficacy and Safety of CGT9486 Versus Placebo in Patients with Indolent or Smoldering Systemic Mastocytosis
Start: Jun 27, 2022
Completion: Apr 30, 2030
NCT06208748
SARC044: a Phase II Trial of Bezuclastinib in Combination with Sunitinib in Patients with GIST
Role: Collaborator
Start: Aug 1, 2024
Completion: Jun 30, 2027
NCT06777316
A Study of an FGFR2/3 Inhibitor (CGT4859) in Patients With Cholangiocarcinoma and Other Advanced Solid Tumors
Start: Jan 22, 2025
NCT07100171
Evaluation of GM101 Injection in Patients With Parkinson's Disease
Phase: Early Phase 1
Start: May 29, 2025
Completion: Feb 17, 2030
NCT07137104
Safety and Preliminary Effectiveness Study of Mesenchymal Stem Cells, HeXell-2020, in Patients With Stable Coronary Artery Disease
Start: Dec 1, 2025
Completion: Jul 31, 2028
NCT07144072
Safety and Tolerability Study of Mesenchymal Stem Cells, HeXell-2020, in Elderly Subjects With Mild to Moderate Frailty Syndrome
Start: Jan 31, 2026
Loading map...